CA1146467A - Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same - Google Patents

Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same

Info

Publication number
CA1146467A
CA1146467A CA000322707A CA322707A CA1146467A CA 1146467 A CA1146467 A CA 1146467A CA 000322707 A CA000322707 A CA 000322707A CA 322707 A CA322707 A CA 322707A CA 1146467 A CA1146467 A CA 1146467A
Authority
CA
Canada
Prior art keywords
substances
antitumor
adjuvant
preparation containing
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000322707A
Other languages
English (en)
French (fr)
Inventor
Shizuo Shimada
Hitoshi Inoue
Tadashi Sudo
Yoshio Furutani
Yoshikazu Fujisawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Toatsu Chemicals Inc
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Application granted granted Critical
Publication of CA1146467A publication Critical patent/CA1146467A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000322707A 1978-03-10 1979-03-02 Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same Expired CA1146467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2651978A JPS54140710A (en) 1978-03-10 1978-03-10 Anti-tumor substance and its preparation
JP26519/1978 1978-03-10

Publications (1)

Publication Number Publication Date
CA1146467A true CA1146467A (en) 1983-05-17

Family

ID=12195716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000322707A Expired CA1146467A (en) 1978-03-10 1979-03-02 Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same

Country Status (7)

Country Link
US (1) US4726947A (enExample)
JP (1) JPS54140710A (enExample)
CA (1) CA1146467A (enExample)
DE (2) DE2954387C2 (enExample)
FR (1) FR2419071A1 (enExample)
GB (1) GB2015876B (enExample)
IT (1) IT1110450B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
JPS5632490A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
FR2466247A1 (fr) * 1979-10-03 1981-04-10 Decroix Guy Preparation immuno-stimulante et application
DE3048699C2 (de) * 1980-12-23 1985-03-28 Chisato Tokio/Tokyo Maruyama Immuntherapeutisches Mittel gegen Tumore, enthaltend als wirksame Komponente ein Lipopolysaccharid
KR940005589B1 (ko) * 1986-04-02 1994-06-21 다이닛뽄세이야꾸 가부시끼가이샤 핵산 또는 엔도톡신의 제거제 및 제거방법
US5527770A (en) * 1993-08-06 1996-06-18 International Gene Group, Inc. Immunotherapeutic agent derived from bacteria
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
DE4422859C2 (de) * 1994-06-30 2000-10-05 Laves Arzneimittel Gmbh Wäßrige Zellextrakte aus Mykobacterien
US5759992A (en) * 1994-08-31 1998-06-02 David Platt Immunotherapeutic agent derived from bacteria and method for its manufacture
US5712123A (en) * 1994-10-07 1998-01-27 Board Of Trustees Of The University Of Illinois Mixture having antitumor activities
ES2196098T3 (es) * 1994-12-28 2003-12-16 Univ Kentucky Res Found Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
WO1996021672A1 (en) * 1995-01-09 1996-07-18 International Gene Group, Inc. Immunotherapeutic agent derived from bacteria
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) * 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
WO1998043655A1 (en) * 1997-04-02 1998-10-08 Bioniche Inc. Use of bacterial cell wall extracts for treating topical disorders and wounds
DE69813231T2 (de) * 1997-06-03 2003-12-04 Itochu Techno-Chemical Inc., Tokio/Tokyo Natürliche antitumor- oder antivirale substanzen und ihre anwendung
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6326357B1 (en) 1997-08-05 2001-12-04 Bioniche Life Sciences Inc. Bacterial cell complex composition and method of use
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US20020068068A1 (en) * 1999-02-02 2002-06-06 Mahan Michael J. Method of creating antibodies and compositions used for same
WO2001044465A2 (en) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
JP4859341B2 (ja) * 2001-07-19 2012-01-25 昭 林 ヒト免疫療法
US7153265B2 (en) * 2002-04-22 2006-12-26 Medtronic Minimed, Inc. Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance
US20040265337A1 (en) * 2002-08-21 2004-12-30 Zsebo Krisztina M. Method of generating an immune response and compositions used for same
US20070160697A1 (en) * 2004-02-27 2007-07-12 Hiroshi Kobayashi Cancer metastasis inhibitory composition
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
US9388400B2 (en) 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
CN106164328B (zh) * 2014-02-12 2018-10-12 李亨坤 薄膜群制造装置、薄膜群、薄膜、紫外线阻隔剂及化妆品
CN114621946B (zh) * 2022-04-07 2023-07-04 施可丰化工股份有限公司 一种防治大豆根腐病的生防菌剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399263A (en) * 1965-04-12 1968-08-27 American Cyanamid Co Stable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acid
GB1188519A (en) * 1966-10-27 1970-04-15 Wellcome Found Method for the Purification of Lipopolysaccharides
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
GB1426042A (en) * 1971-11-26 1976-02-25 Anvar water-soluble immunological adjuvants
NL7308450A (enExample) * 1972-06-20 1973-12-27
FR2189021A1 (en) * 1972-06-20 1974-01-25 Anvar Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues
US4001395A (en) * 1972-06-20 1977-01-04 Agence Nationale De Valorisation De La Recherche (Anvar) Hydrosoluble extracts of mycobacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
SU552744A1 (ru) * 1975-12-25 1977-11-05 Московский Научно-Исследовательский Институт Вакцин И Сывороток Им. И.И. Мечникова Министерства Здравоохранения Ссср Способ получени растворимого коклюшного иммуноадъюванта

Also Published As

Publication number Publication date
US4726947A (en) 1988-02-23
GB2015876B (en) 1982-08-18
IT7920841A0 (it) 1979-03-08
FR2419071A1 (fr) 1979-10-05
DE2908241C2 (de) 1985-10-31
FR2419071B1 (enExample) 1983-02-11
DE2954387C2 (de) 1986-10-09
GB2015876A (en) 1979-09-19
DE2908241A1 (de) 1979-09-13
JPS54140710A (en) 1979-11-01
IT1110450B (it) 1985-12-23
JPS6241214B2 (enExample) 1987-09-02

Similar Documents

Publication Publication Date Title
CA1146467A (en) Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
CA1181691A (en) Vaccinal complex containing a specific antigen and vaccine containing it
CA1212645A (en) Hyaluronic acid from bacterial culture
McBride et al. Biochemical and immunological differences between hydrophobic and hydrophilic strains of Streptococcus mutans
CA1152001A (en) Method for producing pertussis toxoid
Sato et al. Leucocytosis-Promoting Factor of Bordetella pertussis I. Purification and Characterization
IL42545A (en) Water-soluble extracts of mycobacteria their preparation and pharmaceutical compositions containing them
JPH09512708A (ja) グルカンの酵素処理
EP0041897B1 (en) Polysaccharide antigen from streptococcus and vaccines
Goebel et al. The somatic antigen of a phage-resistant variant of phase II Shigella sonnei
CA2018709C (en) Process for removing bacterial endotoxin from gram-negative polysaccharides
Adams et al. Methods for the production of the alpha and theta toxins of Clostridium welchii
KR970002614B1 (ko) 백일해 내독소의 제거방법, 백일해 톡소이드 및 그 제조방법
EP0374178B1 (en) Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli
IE53582B1 (en) Process for the production of capsular polyosides,capsular polyosides obtained thereby,and their application to the preparation of vaccines
Sokal et al. Pyrogen in the urine of febrile patients with Hodgkin's disease
Spizizen [11] Preparation and use of protoplasts
US5039610A (en) Process for removing bacterial endotoxin from gram-negative polysaccharides
US3438865A (en) Preparation of bacterial lipopolysaccharides
JPS6011686B2 (ja) 新規な抗腫瘍剤
CA1276898C (en) Hypocholesterolemically and/or hypotriglyceridemically active rna fractions
Stalheim Biological effects of leptospiral lipids
JPS6230198B2 (enExample)
JPS637530B2 (enExample)
SU1423551A1 (ru) Способ получени фруктозодифосфатальдолазы

Legal Events

Date Code Title Description
MKEX Expiry